17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.
about
The heat shock protein 90 of Plasmodium falciparum and antimalarial activity of its inhibitor, geldanamycinChaperoning steroid hormone signaling via reversible acetylation.Heat shock and other apoptosis-related proteins as therapeutic targets in prostate cancerMolecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast CancerThe importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistanceA phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumorsExpression-based in silico screening of candidate therapeutic compounds for lung adenocarcinomaMedulloblastoma exosome proteomics yield functional roles for extracellular vesiclesInhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancerChemotherapeutic potential of 17-AAG against cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensisMarked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibitionIdentification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesAntibody-based imaging of HER-2: moving into the clinic.Heat shock protein 90: translation from cancer to Alzheimer's disease treatment?Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells.Role of the ubiquitin proteasome system in renal cell carcinoma.Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.The Effect of Tanespimycin (17-AAG) on Radioiodine Accumulation in Sodium-Iodide Symporter Expressing Cells.Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells.Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer.HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humansInduction of nitric oxide synthase-dependent telomere shortening after functional inhibition of Hsp90 in human tumor cells.CYP17A1 inhibitors in castration-resistant prostate cancerAnticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatmentStandard of care and promising new agents for triple negative metastatic breast cancerA phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.Anticancer and antiangiogenic activity of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer therapy.Macrocyclic inhibitors of hsp90Design, synthesis, and evaluation of small molecule Hsp90 probes.Berberine suppresses androgen receptor signaling in prostate cancer.Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancerNew hormonal therapies for castration-resistant prostate cancer.Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PETSNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancerHistone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer.Targeted drug delivery to tumor vasculature by a carbohydrate mimetic peptideHsp90 molecular chaperone inhibitors: are we there yet?
P2860
Q24802251-076CDD15-35CF-42BA-9B1C-CE798FAF26E1Q25257831-E77EB675-0E3E-47BE-9C41-E3861E780E71Q27026128-CEF8C9B9-77F3-492A-970E-3E58181ED33BQ28072513-F61475BE-F2B9-49D1-B8E4-BA7A17AC1133Q28076745-78BD7CA0-EF0C-486A-8CC1-818C220EF996Q28304273-C9671806-C5BF-4E75-959E-B3BAFEAEB1C1Q28476794-91A1B129-C387-46E0-B1FB-D331F6ACA618Q28481626-C747B6FC-7AEE-49D6-A2BD-0CB89587EA53Q28541342-28B7F554-D945-483A-BD30-AF9ED5039429Q28544030-DBA021DF-5276-4F1B-9DEE-57E884D4EB08Q28829301-3A446726-CE5C-4169-B49D-E3590252AA9BQ29617680-987BDB5A-50EC-42C2-9CC4-6457B9D49389Q30423880-F49A14AF-79C7-46B7-9678-03B596A6B3FCQ30855123-6268FD7B-BDDF-4191-9082-33B91D9F5436Q31039889-77AA0EB7-CDED-4580-9791-82D35359A747Q33307879-0E6C1212-EE58-4EEA-956E-FDB8BBB2D989Q33571026-3EAC7122-A6EA-4D5B-AABD-9D011267D28EQ33704634-4EFA03BC-421B-43CB-BE29-420C2F71571FQ33836330-3EE352E9-5741-40BC-926B-6523A1D1C46DQ33896008-7B0375BC-60B1-482F-AD4A-070A7B782BFAQ34112882-55494B77-CAC6-481E-B29D-8C5A4DF25C3DQ34162151-90D9B446-2E1F-4479-BE4E-DCD677198A56Q34353587-E8401128-6E9E-4D0D-8119-9BE0922F1161Q34456638-BAEEE6F8-1E3B-4A1C-A27A-C206320D689FQ34616517-B5353ABE-48BC-41F8-8D67-CD00E2760DD3Q34694211-2FABCE22-F2F2-4DE2-8DD2-E2508EB09006Q34774884-3E39F96C-D3B3-4887-9F56-9893DD983E4CQ34898930-36A55695-8BE6-45F5-A502-A2051F9439B6Q34984769-6D0CFA27-DA68-4E4A-AB87-BF25FCCD9B55Q35017513-06CB231D-1A61-452B-8C35-CDD172378956Q35128528-FD895CEF-4899-4894-B493-FD09BE18BB20Q35159508-A270FC58-BD9B-4604-8782-29113C73BD42Q35194754-22A9E5A9-0F77-43CF-8A91-DB26F64615C1Q35196715-18332E1C-484A-461A-8AE2-5820758194C3Q35350578-0958BE5D-3461-444B-AFEC-38CD143F8173Q35469447-CACC8664-63FE-45E5-B13A-E5BCE8895CADQ35469572-739B429A-8B83-4C08-A1FD-4227691187E6Q35559975-8084099C-D934-4EAB-84CF-EFBBB0CC127FQ35621155-F79BE909-794E-450F-9617-11B0EA6E0316Q35655105-18AFCAB0-A7E6-464F-B1A7-C63AF64E786E
P2860
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
17-Allylamino-17-demethoxygeld ...... of prostate cancer xenografts.
@en
17-Allylamino-17-demethoxygeld ...... of prostate cancer xenografts.
@nl
type
label
17-Allylamino-17-demethoxygeld ...... of prostate cancer xenografts.
@en
17-Allylamino-17-demethoxygeld ...... of prostate cancer xenografts.
@nl
prefLabel
17-Allylamino-17-demethoxygeld ...... of prostate cancer xenografts.
@en
17-Allylamino-17-demethoxygeld ...... of prostate cancer xenografts.
@nl
P2093
P1476
17-Allylamino-17-demethoxygeld ...... of prostate cancer xenografts.
@en
P2093
Brian Higgins
David B Agus
David B Solit
David Verbel
Fuzhong F Zheng
Glenn Heller
Howard I Scher
Maria Drobnjak
Neal Rosen
Pamela N Münster
P304
P407
P577
2002-05-01T00:00:00Z